DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA): $81.11

1.73 (+2.18%)

POWR Rating

Component Grades














  • DVA scores best on the Value dimension, with a Value rank ahead of 85.45% of US stocks.
  • DVA's strongest trending metric is Momentum; it's been moving down over the last 177 days.
  • DVA ranks lowest in Momentum; there it ranks in the 8th percentile.

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 16.3 -- better than 97.95% of US stocks.
  • DVA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.46% of US stocks.
  • DAVITA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 12.37%, greater than the shareholder yield of 85.67% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to DAVITA INC, a group of peers worth examining would be ARRY, QUAD, TAST, SAH, and THC.
  • DVA's SEC filings can be seen here. And to visit DAVITA INC's official web site, go to www.davita.com.

DVA Valuation Summary

  • DVA's price/sales ratio is 0.6; this is 87.23% lower than that of the median Healthcare stock.
  • Over the past 243 months, DVA's price/earnings ratio has gone up 4.2.

Below are key valuation metrics over time for DVA.

Stock Date P/S P/B P/E EV/EBIT
DVA 2023-03-24 0.6 9.7 12.3 16.5
DVA 2023-03-23 0.6 9.5 12.1 16.4
DVA 2023-03-22 0.6 9.7 12.4 16.5
DVA 2023-03-21 0.6 9.9 12.6 16.6
DVA 2023-03-20 0.6 9.9 12.6 16.6
DVA 2023-03-17 0.6 9.7 12.4 16.5

DVA Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 18.38%.
  • The 5 year cash and equivalents growth rate now stands at 1.1%.
  • The 3 year revenue growth rate now stands at 2.81%.
Over the past 15 months, DVA's revenue has gone up $71,074,000.

The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 11,636.97 1,750.736 679.77
2022-06-30 11,626.6 1,607.156 834.158
2022-03-31 11,616.35 2,098.767 903.169
2021-12-31 11,618.8 1,930.876 978.45
2021-09-30 11,580.15 1,885.786 964.75
2021-06-30 11,565.9 1,801.561 863.67

DVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVA has a Quality Grade of B, ranking ahead of 81.19% of graded US stocks.
  • DVA's asset turnover comes in at 0.661 -- ranking 45th of 81 Healthcare stocks.
  • LHCG, NTRA, and CHE are the stocks whose asset turnover ratios are most correlated with DVA.

The table below shows DVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.661 0.312 0.082
2021-06-30 0.666 0.314 0.078
2021-03-31 0.650 0.310 0.074
2020-12-31 0.651 0.308 0.077
2020-09-30 0.648 0.313 0.083
2020-06-30 0.643 0.310 0.082

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.11 Average Broker Recommendation 2 (Hold)

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $81.11 52-week high $124.81
Prev. close $79.38 52-week low $65.28
Day low $79.18 Volume 636,600
Day high $81.20 Avg. volume 672,384
50-day MA $80.46 Dividend yield N/A
200-day MA $81.88 Market Cap 7.33B

DaVita Inc. (DVA) Company Bio

DaVita Inc. provides kidney dialysis services through a network of 2,816 outpatient dialysis centers in the United States, serving 204,200 patients, and 321 outpatient dialysis centers in 10 other countries serving 3,200 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver. (Source:Wikipedia)

DVA Latest News Stream

Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream

Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about DAVITA INC that investors may wish to consider to help them evaluate DVA as an investment opportunity.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

Yahoo | March 31, 2023

DaVita (NYSE:DVA) investors are sitting on a loss of 33% if they invested a year ago

Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

Yahoo | March 29, 2023

Aerospace Executives Go to Trial Over Alleged No-Poach Deals

The Justice Department is still trying to win its first trial over alleged criminal labor-market collusion.

Yahoo | March 26, 2023

DaVita Inc. to Participate in the Barclays 2023 Global Healthcare Conference

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat with investors at the Barclays 2023 Global Healthcare Conference on Tuesday, March 14, 2023, at 3:05 p.m. EDT.

Yahoo | March 13, 2023

Returns On Capital At DaVita (NYSE:DVA) Have Stalled

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...

Yahoo | March 10, 2023

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 0.19%
3-mo 8.62%
6-mo -6.13%
1-year -28.94%
3-year 11.72%
5-year 27.15%
YTD 8.62%
2022 -34.36%
2021 -3.10%
2020 56.47%
2019 45.80%
2018 -28.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8454 seconds.